120 related articles for article (PubMed ID: 1445731)
1. Serum osteocalcin in the management of myeloma.
Williams AT; Shearer MJ; Oyeyi J; Aitchison RG; Newland AC; Schey SA
Eur J Cancer; 1992; 29A(1):140-2. PubMed ID: 1445731
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic value of serum IL-6 level in monoclonal gammopathies.
DuVillard L; Guiguet M; Casasnovas RO; Caillot D; Monnier-Zeller V; Bernard A; Guy H; Solary E
Br J Haematol; 1995 Feb; 89(2):243-9. PubMed ID: 7873373
[TBL] [Abstract][Full Text] [Related]
3. [Acute phase proteins in monoclonal gammapathies].
Dubost JJ; Ristori JM; Soubrier M; Ruivard M; Sauvezie B
Pathol Biol (Paris); 1991 Oct; 39(8):769-73. PubMed ID: 1722302
[TBL] [Abstract][Full Text] [Related]
4. Abnormalities in lymphocyte profile and specificity repertoire of patients with Waldenstrom's macroglobulinemia, multiple myeloma, and IgM monoclonal gammopathy of undetermined significance.
Pilarski LM; Andrews EJ; Serra HM; Ledbetter JA; Ruether BA; Mant MJ
Am J Hematol; 1989 Feb; 30(2):53-60. PubMed ID: 2536515
[TBL] [Abstract][Full Text] [Related]
5. Placental proteins as tumor markers in human monoclonal gammopathies: results in 109 patients.
Morrow JS; Levin DL; Kyle RA; Rosen SW
Tumour Biol; 1985; 6(3):221-32. PubMed ID: 3934736
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal gammopathy: natural history studied with a retrospective approach.
Steingrimsdottir H; Haraldsdottir V; Olafsson I; Gudnason V; Ogmundsdottir HM
Haematologica; 2007 Aug; 92(8):1131-4. PubMed ID: 17650445
[TBL] [Abstract][Full Text] [Related]
7. Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma.
Woitge HW; Pecherstorfer M; Horn E; Keck AV; Diel IJ; Bayer P; Ludwig H; Ziegler R; Seibel MJ
Br J Cancer; 2001 Feb; 84(3):344-51. PubMed ID: 11161399
[TBL] [Abstract][Full Text] [Related]
8. [Biclonal paraproteinemia: macroglobulinemia-myeloma].
Rabago Torre L; Velo Bellver JL; Clemente Ricote G; López de la Riva M; Alcalá-Santaella R
Rev Esp Enferm Apar Dig; 1982 Jul; 62(1):50-5. PubMed ID: 6813927
[No Abstract] [Full Text] [Related]
9. Biochemical markers of bone formation in patients with plasma cell dyscrasias and benign osteoporosis.
Woitge HW; Horn E; Keck AV; Auler B; Seibel MJ; Pecherstorfer M
Clin Chem; 2001 Apr; 47(4):686-93. PubMed ID: 11274019
[TBL] [Abstract][Full Text] [Related]
10. Serum beta 2-microglobulin in patients with monoclonal gammopathies.
Di Giovanni S; Valentini G; Ravazzolo E; Carducci P; Giallonardo P; Maschio C
Int J Biol Markers; 1987; 2(3):169-72. PubMed ID: 3131451
[TBL] [Abstract][Full Text] [Related]
11. Pregnancy-specific beta 1-glycoprotein in serum in monoclonal gammopathies: relationship with serum beta 2-microglobulin, and cellular origin.
Fagnart OC; Tasiaux N; Masson PL
Clin Chem; 1986 Dec; 32(12):2150-4. PubMed ID: 3096609
[TBL] [Abstract][Full Text] [Related]
12. Serum beta-lipoprotein and other specific protein concentrations in patients with immunocytoma.
Shulman G; Lynch SR; Bezwoda WR; Gilich GC
J Clin Pathol; 1976 May; 29(5):458-61. PubMed ID: 180062
[TBL] [Abstract][Full Text] [Related]
13. A phase II trial on alpha-interferon (alpha IFN) effect in patients with monoclonal IgM gammopathy.
Rotoli B; De Renzo A; Frigeri F; Buffardi S; Marcenò R; Cavallaro AM; Ruggeri P; Liso V; Musto P; Andriani A
Leuk Lymphoma; 1994 May; 13(5-6):463-9. PubMed ID: 8069191
[TBL] [Abstract][Full Text] [Related]
14. [Contribution to the evaluation of serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and in individual clinical stages of multiple myeloma].
Scudla V; Petrová P; Minarík J; Pika T; Budíková M; Bacovský J; Repovský S
Vnitr Lek; 2010 Jun; 56(6):591-601. PubMed ID: 20681472
[TBL] [Abstract][Full Text] [Related]
15. Increased vascularization in myeloma.
Laroche M; Brousset P; Ludot I; Mazières B; Thiechart M; Attal M
Eur J Haematol; 2001 Feb; 66(2):89-93. PubMed ID: 11168515
[TBL] [Abstract][Full Text] [Related]
16. [Effectiveness of plasmapheresis on the PF-0.5 blood separator in patients with paraproteinemic hemoblastoses].
Abdullaev OM; Postnikov AA; Prigozhina TA; Likhovetskaia ZM; Mokeeva RA
Ter Arkh; 1987; 59(10):77-81. PubMed ID: 2448887
[TBL] [Abstract][Full Text] [Related]
17. Malignant transformation in IgM monoclonal gammopathy of undetermined significance.
Montoto S; Rozman M; Rosiñol L; Nadal E; Giné E; Aymerich M; Ferrer A; Esteve J; Bosch F; López-Guillermo A; Bladé J; Montserrat E
Semin Oncol; 2003 Apr; 30(2):178-81. PubMed ID: 12720132
[TBL] [Abstract][Full Text] [Related]
18. The significance of carboxy-terminal telopeptide of type I collagen (ICTP) and osteocalcin (OC) in assessment of bone disease in patients with multiple myeloma.
Kuliszkiewicz-Janus M; Małecki R; Zółtaszek A; Zastawny M
Leuk Lymphoma; 2005 Dec; 46(12):1749-53. PubMed ID: 16263577
[TBL] [Abstract][Full Text] [Related]
19. Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ration of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity.
Anagnostopoulos A; Eleftherakis-Papaiakovou V; Kastritis E; Tsionos K; Bamias A; Meletis J; Dimopoulos MA; Terpos E
Br J Haematol; 2007 Jun; 137(6):560-8. PubMed ID: 17451406
[TBL] [Abstract][Full Text] [Related]
20. Serum neural cell adhesion molecule in multiple myeloma and other plasma cell disorders.
Smith SR; Auerbach B; Morgan L
Br J Haematol; 1996 Jan; 92(1):67-70. PubMed ID: 8562413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
